Clinical Trials Directory

Trials / Completed

CompletedNCT00803296

Incretin Effect in Lean and Obese Subjects

The Impact of Obesity and Insulin Resistance on the Incretin Effect in Patients With Type 2 Diabetes and Healthy Subjects

Status
Completed
Phase
Study type
Observational
Enrollment
32 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen · Academic / Other
Sex
Male
Age
18 Years – 70 Years
Healthy volunteers
Accepted

Summary

The incretin effect is markedly reduced in patients with type 2 diabetes. Data support the notion that this deficiency is a consequence of the diabetic state. However, the impact of insulin resistance on the incretin effect in obese individuals who uphold a normal glucose tolerance (NGT) despite their insulin resistant state remains to be elucidated. The primary aim of the present study is to evaluate the separate impact of one of the cornerstones of type 2 diabetic pathophysiology, namely insulin resistance, on the incretin effect in lean and obese patients with type 2 diabetes and in two matched normal-glucose tolerant groups of healthy control subjects.

Conditions

Interventions

TypeNameDescription
OTHEROral glucose tolerance test (OGTT)
OTHERIsoglycemic intravenous glucose infusion

Timeline

Start date
2006-01-01
Primary completion
2008-01-01
Completion
2008-06-01
First posted
2008-12-05
Last updated
2010-01-13

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT00803296. Inclusion in this directory is not an endorsement.